The 2017 annual report provides an overview of the work of the European Medicines Agency (EMA) and highlights last year’s major achievements in protecting and promoting public and animal health in the European Union (EU).
EMA’s annual report draws attention to some of the Agency’s main projects and initiatives, including the first public hearing, the launch of the new EudraVigilance system, the first anniversary of PRIME (PRIority MEdicines) and the new framework and action plan for academia. Additionally, the annual report offers an overview of key Brexit-related dates and shows the steps the Agency took to prepare for the United Kingdom’s departure from the EU together with the European medicines regulatory network.
The report contains key figures, including core statistics that highlight the main outcomes of the Agency’s regulatory procedures and activities, as well as interesting trends and changes observed in recent years.
Finally, it also includes reflections from representatives from EMA’s partners and stakeholders and EMA experts on topics of major interest in medicine and health, namely personalised medicines, the role of pharmacovigilance in innovation, and the collaboration between regulators, health technology assessment bodies and health care payer organisations.